Literature DB >> 18825700

Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS.

Katarina Aleksa1, Alejandro Nava-Ocampo, Gideon Koren.   

Abstract

Ifosfamide (IF), a potent chemotherapeutic agent for solid tumors, is known to cause high rates of nephrotoxicity in children with cancer, which is most likely due to the renal production of the metabolite chloroacetaldehyde. Using plasma samples obtained from pediatric oncology patients, we developed a simple nonderivatizing enantioselective liquid chromatography mass spectrometry method to detect the (R) and (S)-2- and 3-dechloroethylifosfamide metabolites. The (R) and (S)-enantiomers of the 2- and 3-DCEIF (N-3-dechlroethylifosfamide) were detectable in all 22 patients' samples with levels ranging from 9.9 to 238.7 ng/ml for (R)-2-DCEIF, 15.8 to 663.0 ng/ml for (S)-2-DCEIF, 20.8 to 852.8 ng/l for (R)-3-DCEIF and 28.0 to 862.0 ng/ml for (S)-3-DCEIF. In addition, the lower limit of quantification for this method is 1 ng/ml. Future studies should concentrate on (R) or (S) production of the 2-DCEIF and 3-DCEIF and subsequently chloroacetaldehyde formation with the aim of considering the administration of only the (R)-IF as its metabolism results in a lower production of chloroacetaldehyde. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18825700     DOI: 10.1002/chir.20662

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  2 in total

1.  Incorporation of ifosfamide into various essential oils -based nanoemulsions ameliorates its apoptotic effect in the cancers cells.

Authors:  Mayson H Alkhatib; Sahar M AlMotwaa; Huda M Alkreathy
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

2.  A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours.

Authors:  Luz-María Torres; Liliana Rivera-Espinosa; Juan L Chávez-Pacheco; Carlos F Navas; Joel A Demetrio; Radamés Alemón-Medina; Francisca Trujillo; Martín Pérez; Martha M Zapata; Rocío Cárdenas; Citlaltepetl Salinas; Arnoldo Aquino; Rafael Velázquez-Cruz; Manuel-de-Jesús Castillejos
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.